Europe Point-Of-Care Molecular Diagnostics Market (2025 - 2030)

Market Size & Trends

The Europe point-of-care molecular diagnostics market size was estimated at USD 1.43 billion in 2024 and is projected to grow at a CAGR of 7.5% from 2025 to 2030. The growing prevalence of infectious diseases and chronic & genetic disorders such as Turner syndrome, Parkinson’s disease, and Alzheimer’s disease is anticipated to propel the market growth over the forecast period. The rise in disease burden has generated a higher demand for rapid diagnostics. Increasing investments in research and innovation-based product developments are expected to add significant growth opportunities to the Europe point-of-care (POC) molecular diagnostics market.

In primary care settings, point-of-care (POC) molecular diagnostics range from glucose testing to coagulation testing of a complex nature. In numerous health facilities, professionals prefer POC testing over conventional lab testing, owing to reduced time spent on tests and decisions regarding whether further tests are necessary or not. Quick availability of results, cost-efficiency, and improved outcomes are primary benefits of POC molecular diagnostics. Awareness regarding the benefits offered by the method, its significant role in cost reduction, the flexibility provided by the technology, and the minimal requirements associated with its applications have contributed to the growing utilization of POC molecular diagnostics in Europe.

The growing prevalence of infectious diseases primarily adds to the growth in demand experienced by the POC molecular diagnostics market. High sensitivity, capabilities to provide specific results, and inclusion of diverse sample types such as blood, saliva, nasal swabs, urine, and others have increased utilization across healthcare facilities. Numerous infectious diseases can be detected through this method, including influenza, hepatitis B and C, gonorrhea, dengue, and others.

HIV infections continue to influence the well-being of nearly 2.6 million individuals in Europe. In 2023, almost 113,000 individuals were diagnosed with HIV across the European region. The growing prevalence of infectious diseases and awareness regarding the requirement of early treatment diagnosis is expected to drive the demand for effective point-of-care molecular diagnostics products in Europe over the forecast period.

Application Insights

Based on applications, the infectious disease segment dominated the European point-of-care molecular diagnostics market with a revenue share of 60.3% in 2024. Advanced Point-Of-Care (POC) is being developed for a broad range of infectious diseases to meet the growing demand for various testing alternatives, boosting the segment’s growth.

In 2023, EU/EEA countries recorded nearly 713 locally acquired human cases of West Nile virus across 123 different areas of nine countries. According to the European Centre for Disease Prevention and Control (ECDC), Aedes albopictus, responsible for transmitting dengue and a few other infectious diseases, has self-sustaining populations in nearly 13 EU/EEA countries. Growing demand for rapid tests, the rising burden on the healthcare ecosystem, and the focus of facilities on reducing costs without compromising the quality of services and diagnostics are expected to drive the growth of this segment.

The oncology segment is expected to experience the fastest CAGR from 2025 to 2030. Increasing demand for faster cancer test results, the requirement for accurate detection in cancer tests, and the dependability of personalized treatment decisions on these tests are primarily influencing the growth of this segment. Point-of-care tests are preferred for capabilities to identify cancer biomarkers such as circulating tumor DNA (ctDNA) or specific genetic mutations quickly, which can assist healthcare professionals in early intervention and potentially improve patient outcomes. According to WHO, nearly 20.0% of deaths are caused by cancer in the European Region. Growing awareness regarding early detection and intervention benefits is expected to drive growth for oncology applications of point-of-care molecular diagnostics.

Test Location Insights

POC diagnostics accounted for the highest revenue share in 2024. POC testing offers quick results and portability as key benefits. Molecular testing assists in recognizing the genetic material of an infectious agent, significantly enhancing the diagnosis and management of infectious diseases. Numerous tests are being used outside of hospitals since they are quick, portable, and affordable.

OTC diagnostics is projected to experience the fastest CAGR of 13.1% over the forecast period. Numerous market participants have launched novel diagnostic kits used for the identification of various infectious diseases. Demand for convenient health solutions and inclination towards at-home tests are expected to drive the growth of this market. OTC diagnostic products offer early diagnosis and constant patient monitoring, as well as curb costs associated with healthcare establishments and practitioners.

Technology Insights

The PCR-based segment dominated the European point-of-care molecular diagnostics industry with a revenue share of 63.7% in 2024. Rapid and accurate test results offered by PCR technology-driven testing, growing demand for home testing products, and the ability to provide on-site detection of various diseases are some of the key driving factors. Major benefits associated with PCR technology, such as speed, efficiency, innovation such as microfluidic technologies, and utilization of amplification techniques, are expected to add lucrative growth opportunities.

The genetic sequencing-based segment is projected to experience the fastest CAGR from 2025 to 2030. This is attributed to factors such as growing demand for rapid pathogen testing, increasing utilization during outbreaks of infectious diseases, and rising use of technology for identifying specific mutations, such as chronic myeloid leukemia (CML), during cancer tests.

End Use Insights

Based on end use, the decentralized labs segment held the largest revenue share of 35.6% in 2024. The growth of this segment is primarily influenced by factors such as the prevalence of infectious diseases in Europe, the use of real-time monitoring of biomarkers, the rapid turnaround time offered by POC molecular diagnostics, cost efficiency, and accessibility in comparatively remote areas. The use of POC molecular diagnostics also assists in streamlining processes and reducing errors in decentralized labs.

The home care segment is projected to experience the fastest CAGR during the forecast period. This is attributed to the cost-effectiveness and comfort of point-of-care molecular diagnostics provided to patients at home. POC molecular diagnostics empowers patients to address healthcare challenges at home and make decisions instantly.

Country Insights

Germany point-of-care molecular diagnostics market dominated the European market with a revenue share of 19.4% in 2024. This is attributed to factors such as the presence of advanced healthcare infrastructure, technological advancements, and increasing application areas. The rise in chronic diseases such as cancer and the country's large aging population are expected to add growth opportunities.

The point-of-care molecular diagnostics market in the UK is projected to experience the fastest CAGR during the forecast period. This market's growth is primarily driven by outbreaks of infectious diseases, the prevalence of chronic diseases, and the growing burden on the healthcare ecosystem.

Key Europe Point-Of-Care Molecular Diagnostics Company Insights

Some major companies in the Europe point-of-care molecular diagnostics industry include F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Bayer AG, Nova Biomedical, Danaher, and others. To address growing demand and market competition driven by innovation, key market participants have embraced strategies such as new product developments, investments in research & development, incorporating advanced technologies, and more.

• Hoffmann-La Roche Ltd., commonly referred to as Roche, offers a diverse range of medical diagnostic solutions, tests, and technologies. Its point-of-care molecular diagnostics offering features a quick PCR near-patient testing solution, cobas liat, commonly used for tests related to strep throat, influenza, respiratory syncytial virus (RSV), Clostridioides difficile (C. diff), and more.

• bioMérieux,a diagnostics technology and solutions provider, offers tests, equipment, and software solutions associated with microbiology, molecular biology, and immunoassays. Its point-of-care portfolio includes the BIOFIRE SPOTFIRE System, BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel, and others.

Recent Developments

• In September 2024, Roche launched innovation-based TAGS technology capable of simultaneously detecting 12 respiratory viruses. Newly unveiled TAGS (Temperature-Activated Generation of Signal) technology supports the simultaneous detection of 15 targets in a single patient sample through high throughput molecular diagnostic analyzers.

Europe Point-Of-Care Molecular Diagnostics Market